Liposomal bupivacaine has been approved by the US Food and Drug Administration for local infiltration for pain relief after bunionectomy and hemorrhoidectomy. 

Market Analysis and Insights: Global and China Liposomal Bupivacaine Market
This report focuses on global and China Liposomal Bupivacaine market.
In 2020, the global Liposomal Bupivacaine market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In China the Liposomal Bupivacaine market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Liposomal Bupivacaine Scope and Market Size
Liposomal Bupivacaine market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Liposomal Bupivacaine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Liposomal Bupivacaine market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.

Segment by Type
20ml
10ml

Segment by Application
Veterinary
Human

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Pacira Pharmaceuticals